Rep. Jefferson Shreve Sells IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares

Representative Jefferson Shreve (R-Indiana) recently sold shares of IDEXX Laboratories, Inc. NASDAQ: IDXX. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $100,001 and $250,000 in IDEXX Laboratories stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

IDEXX Laboratories Stock Up 2.8%

NASDAQ:IDXX traded up $15.22 on Friday, reaching $565.19. The stock had a trading volume of 1,071,473 shares, compared to its average volume of 425,413. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $526.59 and a 200 day moving average of $467.17. The stock has a market cap of $45.45 billion, a P/E ratio of 52.24, a price-to-earnings-growth ratio of 4.11 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $568.47.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.71 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IDXX. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price objective for the company. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Stifel Nicolaus increased their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research report on Wednesday, July 2nd. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $557.88.

Hedge Funds Weigh In On IDEXX Laboratories

Large investors have recently modified their holdings of the stock. NorthRock Partners LLC raised its stake in IDEXX Laboratories by 84.0% during the second quarter. NorthRock Partners LLC now owns 1,906 shares of the company's stock worth $1,022,000 after acquiring an additional 870 shares during the period. Verdence Capital Advisors LLC acquired a new stake in IDEXX Laboratories during the second quarter worth about $806,000. Envestnet Portfolio Solutions Inc. raised its stake in IDEXX Laboratories by 34.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 22,444 shares of the company's stock worth $12,038,000 after acquiring an additional 5,795 shares during the period. Sequoia Financial Advisors LLC raised its stake in IDEXX Laboratories by 39.1% during the second quarter. Sequoia Financial Advisors LLC now owns 2,694 shares of the company's stock worth $1,445,000 after acquiring an additional 757 shares during the period. Finally, Montrusco Bolton Investments Inc. raised its stake in IDEXX Laboratories by 50.3% during the second quarter. Montrusco Bolton Investments Inc. now owns 429,409 shares of the company's stock worth $224,153,000 after acquiring an additional 143,641 shares during the period. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.98% of the stock is currently owned by company insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.